Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLS32015 + pomalidomide
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (QLS32015), Oral (pomalidomide)
01
Overview
QLS32015 + pomalidomide is a combination of two drugs, **QLS32015**, an investigational bispecific T-cell engager targeting CD3 and GPRC5D (G-protein coupled receptor family C group 5member D), and **pomalidomide**, an FDA-approved immunomodulatory agent derived from thalidomide[7][4]. QLS32015 is designed to stimulate T-cells (through CD3) and inhibit GPRC5D, a target relevant in multiple myeloma, while pomalidomide enhances immune anti-tumor activity via cereblon modulation, increases T and NK cell function, and inhibits pro-inflammatory cytokines and tumor growth[4][7]. The combination is intended for the treatment of relapsed or refractory multiple myeloma and is currently being tested in Phase II clinical trials[1][5]. QLS32015 was developed by Qilu Pharmaceutical; pomalidomide is marketed as Pomalyst and Imnovid and manufactured by several companies globally[1][7][4].
- Brand names
- Pomalidomide Viatris
- Other names
- QLS32015 (for the investigational bispecific)pomalidomida
02
Targets
CD3 (T-cell surface glycoprotein CD3)CRBN (Cereblon)GPRC5DIKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on QLS32015 + pomalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLS32015 + pomalidomide.